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Abstract
Purpose Report the efficacy and safety of pasireotide sc
in patients with Cushing’s disease during an open-ended,
open-label extension to a randomized, double-blind,
12-month, Phase III study.
Methods 162 patients entered the core study. 58 patients
who had mean UFC B ULN at month 12 or were bene-
fiting clinically from pasireotide entered the extension.
Patients received the same dose of pasireotide as at the end
of the core study (300–1,200 lg bid). Dose titration was
permitted according to efficacy or drug-related adverse
events.
Results 40 patients completed 24 months’ treatment. Of
the patients who entered the extension, 50.0 % (29/58) and
34.5 % (20/58) had controlled UFC (UFC B ULN) at
months 12 and 24, respectively. The mean percentage
decrease in UFC was 57.3 % (95 % CI 40.7–73.9; n = 52)
and 62.1 % (50.8–73.5; n = 33) after 12 and 24 months’
treatment, respectively. Improvements in clinical signs of
Cushing’s disease were sustained up to month 24. The most
frequent drug-related adverse events in patients who
received C1 dose of pasireotide (n = 162) from core
baseline until the 24-month cut-off were diarrhea (55.6 %),
nausea (48.1 %), hyperglycemia (38.9 %), and cholelithi-
asis (31.5 %). No new safety issues were identified during
the extension.
Conclusions Reductions in mean UFC and improvements
in clinical signs of Cushing’s disease were maintained over
24 months of pasireotide treatment. The safety profile of
pasireotide is typical for a somatostatin analogue, except
for the frequency and degree of hyperglycemia; patients
should be monitored for changes in glucose homeostasis.
Pasireotide represents the first approved pituitary-targeted
treatment for patients with Cushing’s disease.
Clinical Trials Registration Number: NCT00434148. On behalf of the
Pasireotide B2305 Study Group.
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Introduction
Cushing’s disease is a rare and debilitating disorder of
hypercortisolism caused by an adrenocorticotropic hor-
mone (ACTH)-secreting pituitary tumor [1–3]. Cushing’s
disease is associated with increased morbidity and mor-
tality due to the development of several hypercortisolism-
induced clinical complications, including central obesity,
insulin resistance, glucose intolerance, diabetes mellitus,
hypertension and cardiovascular disease, as well as osteo-
porosis, psychiatric disorders and increased susceptibility
to infection [1, 4, 5]. Transsphenoidal adenomectomy is the
first-line therapy for most patients with Cushing’s disease.
Second-line treatment options include repeat surgery,
radiotherapy, bilateral adrenalectomy and medical therapy.
Pasireotide (Signifor) is a multireceptor-targeted
somatostatin analogue with a high affinity for somatostatin
receptor subtype 5 (sst5), as well as activating sst1,2,3 [6].
Pasireotide targets the underlying cause of Cushing’s dis-
ease by activating sst5 on corticotroph adenomas, resulting
in the inhibition of ACTH secretion [7, 8].
The efficacy and safety of pasireotide has recently been
evaluated in the largest prospective study of a medical
therapy in Cushing’s disease [9]. This randomized, Phase
III study led to the approval of pasireotide in the European
Union, the United States of America and other countries
worldwide for use in adult patients with Cushing’s disease
for whom surgery is not an option or has failed [10, 11].
12 months’ treatment with pasireotide was associated with
a rapid and sustained reduction in urinary free cortisol
(UFC) and significant improvements in the clinical signs
and symptoms of Cushing’s disease [9]. The safety profile
of pasireotide in this study was similar to that of other
somatostatin analogues, except for the increased frequency
and degree of hyperglycemia. Reported here are the safety
and efficacy results for an additional 12 months of
pasireotide treatment in a planned, open-label extension to
this Phase III study.
Methods
Participant eligibility criteria
This open-label study was a planned extension to a
12-month, multicenter, randomized, Phase III study
(Clinicaltrials.gov, NCT00434148) [9]. Patients who were
eligible for entry into the core study were adults
(C18 years of age) with confirmed de novo, persistent or
recurrent Cushing’s disease. Cushing’s disease was defined
by a mean 24-h UFC level (calculated from four UFC
samples collected within 14 days) C1.5 times the upper
limit of normal (ULN; 145 nmol/24 h [52.5 lg/24 h]), a
morning plasma ACTH level C5 ng/L (1.1 nmol/L), and a
confirmed pituitary source of Cushing’s syndrome. Key
exclusion criteria were tumor compression of the optic
chiasm causing visual-field defects, pituitary irradiation
within the previous 10 years, mitotane treatment within the
previous 6 months, symptomatic cholelithiasis, a glycated
hemoglobin (HbA1c) level [8 %, and de novo Cushing’s
disease in patients who were surgical candidates. Patients
with a mean UFC level B ULN at month 12 or those
considered, at the discretion of the investigator, to be
achieving significant clinical benefit from pasireotide were
eligible for entry into the extension.
The study was approved by the independent ethics
committee, research ethics board or institutional review
board at each center and complied with the ICH Harmo-
nized Tripartite Guidelines for Good Clinical Practice, the
Declaration of Helsinki and local laws. All patients pro-
vided written informed consent. All researchers had full
access to all of the data in the study.
Study design
At the beginning of the core study (i.e., core baseline), 162
patients were randomly assigned to receive subcutaneous
(sc) pasireotide at a dose of 600 lg (n = 82) or 900 lg
(n = 80) twice daily (bid). Patients with a mean UFC level
B2 9 ULN and not exceeding the baseline level at month
3 continued to receive their randomly assigned dose; all
others had a dose increase of 300 lg bid. At month 6,
patients entered an open-label phase until month 12; during
this phase, dose increases of 300 lg bid were permitted in
patients with UFC [ ULN. Patients entering the open-
ended extension continued, without interruption to treat-
ment, on the same dose of pasireotide they were receiving
at the end of the 12-month core study. During the exten-
sion, the dose could be increased by 300 lg bid at any time
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if UFC was higher than the ULN. The maximum permitted
dose of pasireotide was 1,200 lg bid. In the event of drug-
related adverse events (AEs), dose reductions of 300 lg
bid were allowed.
Efficacy assessments
During the extension, UFC, fasting serum cortisol and
plasma ACTH levels were measured at 3-month intervals.
The UFC level was calculated as the mean value from two
consecutive 24-h urine samples; patients were considered to
have controlled (UFC B ULN), partially controlled
(UFC [ ULN but C50 % decrease from core baseline), or
uncontrolled (UFC [ ULN without a C50 % decrease from
core baseline) UFC. Patients with a missing mean UFC value
were considered to be uncontrolled at the corresponding time
point; patients who discontinued treatment were considered
to be uncontrolled at all subsequent time points.
Assay details
UFC level was determined by high-performance liquid
chromatography [Alliance 2795 High Throughput Sys-
tem, Waters Corp, Milford, MA, USA; normal UFC range
30–145 nmol/24 h (10.8–52.5 lg/24 h)], as described
previously [12]. All samples were analyzed by central
laboratories (Eurofins Medinet BV, Breda, The Nether-
lands; CRL Medinet Inc, Lenexa, KS, USA; and Eurofins
Technology Services [Suzhou] Co Ltd, Suzhou, China).
Pre-dose blood samples were tested for serum cortisol
(assay: ADVIA Centaur CP Immunoassay System, Sie-
mens Healthcare Diagnostics Inc, Tarrytown, NY, USA)
and plasma ACTH (assay: Immulite 2000 ACTH kit,
DPC, Los Angeles, CA, USA).
Clinical signs and safety assessments
Systolic and diastolic blood pressure, body weight, body
mass index (BMI), and total and low-density lipoprotein
(LDL) cholesterol levels were assessed at 3-month inter-
vals during the extension. At each visit, hematological and
blood biochemical measurements (including fasting blood
glucose and HbA1c levels) and urinalysis were performed.
Patient diabetic status was defined as normal glucose tol-
erance (HbA1c \ 5.7 %), pre-diabetes (HbA1c C5.7 to
\6.5 %), and diabetes (HbA1c C 6.5 %); patients with
HbA1c levels C8 % were considered to have poorly con-
trolled diabetes. AEs were graded according to Common
Terminology Criteria for Adverse Events (CTCAE) version
3.0 [13]. All medications, other than study drug, adminis-
tered during the study were recorded; however, dose
information for concomitant medications was not recorded
during the study.
Statistical analysis
Analysis of mean UFC, serum cortisol, plasma ACTH, and
clinical signs was performed for those patients who had
evaluable measurements at the specific time point; for
calculations of mean change, only those patients who had
evaluable measurements at both core baseline and the
specific time point were included. All randomized patients
who received at least one dose of pasireotide (n = 162)
were included in the analysis of safety and AEs, unless
otherwise stated. The 24-month data cut-off for AE analysis
occurred when the last ongoing patient reached 24 months’
pasireotide treatment (25 March 2011). As such, a number of
patients included in the safety analysis received[24 months
of pasireotide treatment. The study was not powered to
detect statistically significant differences between dose
groups, and these comparisons were not performed.
Results
Patients
Seventy-eight of the 162 patients (48.1 %) who entered the
core study completed 12 months’ pasireotide treatment (39
patients each in both the 600 and 900 lg bid groups). Of
these 78 patients, 58 entered the optional extension phase;
the reasons why patients chose not to enter the extension
were not consistently recorded. Demographics and charac-
teristics for the 58 patients who entered the extension (26
and 32 patients in the 600 and 900 lg bid groups, respec-
tively) are shown in Table 1. The mean total duration of
treatment from core baseline up to the 24-month data cut-
off for those all patients who received C1 dose of pasireo-
tide (n = 162) was 14 months (range 0–50) and for those
who entered the extension phase (n = 58) was 27 months
(range 12–50); 53, 46, 41, and 40 patients completed 15, 18,
21, and 24 months’ treatment, respectively, while 10
patients received C36 months’ treatment. The mean daily
dose of pasireotide for patients randomized to the 600 and
900 lg arms was 1,185 and 1,739 lg for months 0–6, 1,420
and 1,813 lg for months 6–12, 1,509 and 1,766 lg for
months 12–18, and 1,500 and 1,620 lg for months 18–24.
Efficacy
Urinary free cortisol
Among the 58 patients who entered the extension, con-
trolled UFC (UFC B ULN) was achieved at month 12 (end
of the core study/extension baseline) by 50.0 % (29/58) of
patients; 20.7 % (12/58) and 29.3 % (17/58) of patients had
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partially controlled UFC (UFC [ ULN but C50 %
decrease from core baseline) and uncontrolled UFC,
respectively. During the core phase, the proportion of
patients achieving UFC B ULN was dose dependent; at
month 12, 38.5 % (10/26) of patients in the 600 lg bid
group and 59.4 % (19/32) of patients in the 900 lg bid
group had controlled UFC (Fig. 1). This dose–response
relationship was less apparent after 15 months of treat-
ment; at month 24, 30.8 % (8/26) and 37.5 % (12/32) of
patients in the 600 and 900 lg bid groups, respectively,
had controlled UFC.
The mean percentage decrease in UFC level from core
baseline during the first 12 months of treatment [57.3 %
(95 % CI 40.7 to 73.9)] in patients who entered the
extension phase (n = 58) was maintained throughout the
24-month study period (Fig. 2); the mean percentage
decrease in UFC level from baseline to month 18 and
month 24 was 62.3 % (53.4 to 71.1) and 62.1 % (50.8 to
73.5), respectively.
Of the 29 patients who had controlled UFC levels at the
end of the core study, 48.3 % (14/29) and 10.3 % (3/29)
had controlled or partially controlled UFC levels, respec-
tively, at month 24, while 41.4 % (12/29) were uncon-
trolled. Six of the 12 patients who were classified as
uncontrolled at month 24 discontinued treatment during the
extension (reasons for discontinuation: AE, n = 2; consent
withdrawal, n = 2; unsatisfactory therapeutic effect,
n = 2); at last available assessment, two of these patients
were controlled, two were partially controlled, and two
were uncontrolled. One additional patient, who had
controlled UFC at month 12 and at last available assess-
ment, had a missing mean UFC value at month 24.
Of the 12 patients who had partially controlled UFC at
month 12, 16.7 % (2/12) remained partially controlled,
25.0 % (3/12) had controlled UFC, and 58.3 % (7/12) had
Fig. 1 Proportion of patients with UFC B ULN at time points up to
month 24 in the 58 patients who entered the open-ended extension.
The numbers shown above each bar represent the total number of
patients in each treatment group with UFC B ULN at the specific
time point. Patients with missing data are classed as non-responders at
the given time point; patients who discontinued are classed as non-
responders at subsequent time points. The pasireotide 600 and 900 lg
dose groups represent the randomly assigned treatment at core
baseline; patients were not necessarily receiving their randomized
dose at each time point
Table 1 Summary of core
baseline demographics and
characteristics (by dose group)
of patients who entered the
open-ended extension
* Baseline UFC was calculated
if C3 samples were collected
Characteristic Pasireotide 600 lg bid
(N = 26)
Pasireotide 900 lg bid
(N = 32)
Overall
(N = 58)
Females, n (%) 20 (77) 31 (97) 51 (88)
Age, years
Mean (range) 40.4 (18–67) 41.4 (19–58) 40.9 (18–67)
C65 years, n (%) 1 (4) 0 (0) 1 (2)
Time since diagnosis, months
Mean (range) 62 (0.8–341.8) 57 (0.1–216.3) 59 (0.1–341.8)
Previous treatment, n (%)
Surgery 20 (77) 23 (72) 43 (74)
Medication 10 (38) 17 (53) 27 (47)
Pituitary irradiation 3 (12) 3 (9) 6 (10)
Cushing’s disease status, n (%)
De novo 5 (19) 6 (19) 11 (19)
Persistent/recurrent 21 (81) 26 (81) 47 (81)
UFC, nmol/24 h
Baseline measurement, n* 24 29 53
Mean 842 529 671
Median (range) 764 (220–4,564) 448 (195–1,758) 511 (195–4,564)
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uncontrolled UFC levels at month 24. Three of the 17
(17.6 %) patients who were uncontrolled at month 12
achieved controlled UFC levels at month 24, while 14
(82.4 %) remained uncontrolled.
Serum cortisol and plasma ACTH
Sustained mean reductions in serum cortisol and plasma
ACTH levels were observed throughout the 24-month
treatment period (Fig. 2). The mean percentage decrease in
morning serum cortisol level at months 12 and 24 was
14.9 % (95 % CI 7.8 to 22.0) and 18.0 % (95 % CI 5.8 to
30.2), respectively. The mean percentage decrease in
plasma ACTH was 17.8 % (95 % CI 5.2 to 30.5) and
14.7 % (95 % CI 2.6 to 26.9) at months 12 and 24,
respectively.
Clinical signs
Marked improvements in clinical signs of Cushing’s dis-
ease were observed during the 24-month study; these
effects were observed by month 12 and were sustained
until month 24 (Fig. 3). Mean changes from core baseline
following 12 months of pasireotide treatment for those
patients who entered the extension were: systolic blood
pressure, -8.4 mmHg (95 % CI -12.3 to -4.5; -5.6 %
change); diastolic blood pressure, -4.0 mmHg (95 % CI
-6.9 to -1.2; -3.6 % change); weight, -7.7 kg (95 % CI
-9.3 to -6.1; -9.1 % change); and BMI, -2.8 kg/m2
(95 % CI -3.4 to -2.3; -9.1 % change). Further
improvements in several clinical signs were observed fol-
lowing extended pasireotide treatment; mean changes from
core baseline at 24 months were: systolic blood pressure,
-11.3 mmHg (95 % CI -15.0 to -7.5; -8.2 % change);
diastolic blood pressure, -7.2 mmHg (95 % CI -10.4 to
-3.9; -7.6 % change); weight, -8.7 kg (95 % CI -11.1
to -6.2; -9.6 % change); and BMI -3.2 kg/m2 (95 % CI
-4.0 to -2.3; -9.6 % change). Mean changes from core
baseline in total and LDL cholesterol levels were
-0.6 mmol/L (95 % CI -0.8 to -0.3; -8.5 % change)
and -0.4 mmol/L (95 % CI -0.7 to -0.2; -10.4 %
change), respectively, at month 12 and -0.4 mmol/L
(95 % CI -0.8 to -0.1; -5.8 % change) and -0.3 mmol/
L (95 % CI -0.6 to 0.0; -3.0 % change), respectively, at
month 24.
Safety and tolerability
Of the patients who entered the open-ended extension,
46.6 % (27/58) had discontinued the study prior to the
24-month data cut-off: 12 because of consent withdrawal, 10
because of an unsatisfactory therapeutic effect, and five
because of AEs. Overall, 98.1 % (159/162) of patients who
received at least one dose of pasireotide reported at least one
AE, regardless of study-drug relationship, from core base-
line until the 24-month data cut-off. Of these patients,
48.4 % experienced AEs with a maximum grade of 1 or 2
(based on CTCAE criteria). The most frequently observed
AEs were gastrointestinal disorders, which were reported in
81.5 % of patients. The most common AEs suspected to be
study drug related were diarrhea (55.6 %), nausea (48.1 %),
hyperglycemia (38.9 %), and cholelithiasis (31.5 %)
Fig. 2 Mean (±SE) a UFC, b serum cortisol, and c plasma ACTH
levels from baseline up to month 24 in the 58 patients who entered the
open-ended extension. The total numbers of patients with evaluable
measurements for UFC, serum cortisol, and plasma ACTH are shown
beneath each graph
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(Table 2); 11.7 % and 8.6 % of patients experienced grade 3
or 4 hyperglycemia and diabetes mellitus, respectively.
Newly occurring AEs during the extension phase that were
suspected to be drug related included cholelithiasis (n = 3),
diabetes mellitus, nausea, fatigue, diarrhea (n = 2 each),
headache and elevated alanine transaminase (n = 1 each).
No new safety issues were identified after the first 12-month
data cut-off. Serious AEs (SAEs) were reported by 25.9 %
(42/162) of patients who received at least one dose of pa-
sireotide; two patients who did not have an SAE up to the
core study data cut-off subsequently experienced C1 SAE.
There were no deaths throughout the entire study.
Concomitant medication
Thirty-six patients (62.1 %) received antihypertensive
medication at some stage during the core study or exten-
sion. Of the 28 patients who were not receiving antihy-
pertensive medication at core baseline, six received C1
antihypertensive agent at some stage during the core study
or extension; eight of the 30 patients who were receiving
antihypertensive medication at core baseline received C1
additional agent. Thirty-five patients (60.3 %) received
antidiabetic medication at some stage during the core study
or extension. Of the 50 patients who were not receiving
antidiabetic medication at core baseline, at least one anti-
diabetic medication was initiated in 27 patients; five of the
eight patients who were receiving antidiabetic medication
at core baseline received C1 additional agent during the
core study or extension. Only one of 24 patients who did
not receive any antidiabetic medication during the core
study initiated an antidiabetic treatment during the exten-
sion phase. One additional patient had an increase in the
number of antidiabetic medications they received during
the extension phase compared with the core study.
Blood glucose
Mean fasting plasma glucose and HbA1c levels increased
soon after initiation of pasireotide therapy; peak fasting
glucose levels were achieved by month 1 and stabilized
thereafter. Mean HbA1c increased from 5.8 % at core
baseline to 7.2 % and 6.8 % following 12 and 24 months’
treatment, respectively (Fig. 4a); for the 58 patients who
entered the extension, mean HbA1c was similar at month 24
compared with extension baseline (6.8 vs. 7.0 %). Simi-
larly, mean fasting plasma glucose increased from
97.8 mg/dL at core baseline to 117.7 mg/dL at month 12
and then remained stable until month 24 (119.5 mg/dL)
(Fig. 4b); for the 58 patients who entered the extension,
mean fasting plasma glucose was similar at month 24
compared with extension baseline (119.5 vs. 113.1 mg/dL).
For those patients who did not receive antidiabetic
medication during the 24-month study period, 21 had
baseline and post-baseline HbA1c measurements; 61.9 %
(13/21) of these patients had a last available HbA1c level
indicating a worse diabetic status than at core baseline.
Two patients had missing values at core baseline. Further
details can be found in the Supplementary Appendix.
Most patients had an increase in HbA1c relative to
baseline at some point after initiation of pasireotide treat-
ment. At baseline, 49.4 % (80/162) of patients had normal
HbA1c levels (HbA1c \5.7 %); 76.3 % (61/80) of these
Fig. 3 Mean UFC (±SE) and a systolic blood pressure, b diastolic
blood pressure, and c weight up to month 24 in the 58 patients who
entered the open-ended extension. The total numbers of patients
included in the analyses of mean UFC level and mean signs and
symptoms scores are shown beneath each graph. DBP diastolic blood
pressure, SBP systolic blood pressure
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patients had last available HbA1c levels in a category
indicating a worse diabetic status than at core baseline
(Table 3). Overall, 16.0 % (26/162) of patients had base-
line HbA1c levels in the diabetic range (HbA1c C6.5 %). Of
the patients who had baseline HbA1c levels in the diabetic
range and C1 post-baseline measurement, all had at least
one post-baseline value indicating poorly controlled dia-
betes (HbA1c levels C 8 %; data not shown) and a last
available value indicating diabetes mellitus or poorly
controlled diabetes (Table 3).
Discussion
This long-term study reports the efficacy and safety of
pasireotide sc following 24 months of treatment in patients
with de novo, persistent or recurrent Cushing’s disease [9].
Initiation of pasireotide treatment resulted in rapid and
sustained mean reductions in UFC, serum cortisol and
ACTH levels, which were accompanied by persistent
improvements in clinical signs of Cushing’s disease. Pa-
sireotide was generally well tolerated over the 24-month
treatment period.
In the 58 patients who completed the core study and
entered the extension, the mean percentage decrease in
UFC level from baseline following 12 and 24 months of
pasireotide treatment was 57–62 % and was similar in both
dose groups. There was an overall decrease in the pro-
portion of patients with controlled UFC at month 24
compared with month 12; 50.0 % (29/58) and 34.5 % (20/
58) of patients had controlled UFC at month 12 and month
24, respectively. As patients without UFC values were
considered to be uncontrolled, the lack of UFC values at
month 24 for three patients (two patients had discontinued
and one patient had a missing UFC value) who had
(a)
(b)
Fig. 4 Mean (±SE) a HbA1c and b fasting plasma glucose over time
from baseline up to 24-month data cut-off in the 162 patients who
received at least one dose of pasireotide
Table 2 Most frequently reported AEs suspected to be study drug related (occurring in C10 % of patients in either dose group) up to the
24-month data cut-off in the 162 patients who received at least one dose of pasireotide
AE, n (%) Pasireotide 600 lg bid (N = 82) Pasireotide 900 lg bid (N = 80) Overall (N = 162)
Grades 1 and 2 All grades Grades 1 and 2 All grades Grades 1 and 2 All grades
Diarrhea 44 (53.7) 47 (57.3) 42 (52.5) 43 (53.8) 86 (53.1) 90 (55.6)
Nausea 34 (41.5) 35 (42.7) 40 (50.0) 43 (53.8) 74 (45.7) 78 (48.1)
Hyperglycemia 23 (28.0) 30 (36.6) 21 (26.3) 33 (41.3) 44 (27.2) 63 (38.9)
Cholelithiasis 27 (32.9) 28 (34.1) 22 (27.5) 23 (28.8) 49 (30.2) 51 (31.5)
Abdominal pain 13 (15.9) 14 (17.1) 17 (21.3) 19 (23.8) 30 (18.5) 33 (20.4)
Diabetes mellitus 9 (11.0) 17 (20.7) 10 (12.5) 16 (20.0) 19 (11.7) 33 (20.4)
Fatigue 6 (7.3) 7 (8.5) 12 (15.0) 14 (17.5) 18 (11.1) 21 (13.0)
HbA1c elevation 9 (11.0) 10 (12.2) 7 (8.8) 7 (8.8) 16 (9.9) 17 (10.5)
ALT elevation 9 (11.0) 10 (12.2) 3 (3.8) 5 (6.3) 12 (7.4) 15 (9.3)
Type 2 diabetes mellitus 6 (7.3) 10 (12.2) 2 (2.5) 5 (6.3) 8 (4.9) 15 (9.3)
Headache 5 (6.1) 6 (7.3) 8 (10.0) 8 (10.0) 13 (8.0) 14 (8.6)
Vomiting 1 (1.2) 2 (2.4) 7 (8.8) 8 (10.0) 8 (4.9) 10 (6.2)
AEs are ordered based on the frequency of events. ALT alanine transaminase. The 24-month data cut-off for AE analysis occurred when the last
ongoing patient reached 24 months’ pasireotide treatment. As such, a number of patients received[24 months’ treatment. At the 24-month data
cut-off, the duration of treatment for those patients who received C1 dose of pasireotide ranged from 0 to 50 months (mean 14 months)
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controlled UFC at their last available assessment as well as
at month 12 may have contributed to the observed decrease
in number of responders between months 12 and 24. While
escape from response has been reported during long-term
treatment of Cushing’s disease with the dopamine receptor
agonist cabergoline [14, 15], a similar phenomenon has not
been shown for pasireotide. Nevertheless, it is possible that
a loss of pasireotide efficacy in a small number of patients
may have contributed to the reduction in the number of
responders during the extension study.
Reductions in UFC with pasireotide treatment were
accompanied by rapid decreases in mean serum cortisol and
plasma ACTH levels, which were initially observed in the
core study and were maintained for the duration of the
extension (serum cortisol and plasma ACTH levels
decreased by 18.0 and 14.7 %, respectively, from core
baseline to month 24). Sustained improvements in a number
of clinical signs, including systolic and diastolic blood
pressure, weight, and total cholesterol level, were also
observed; changes in signs and symptoms during 12 months
of treatment with pasireotide have been recently reported
[16]. The data from the current 24-month study suggest that
the initial efficacy and clinical benefit of pasireotide in
patients with Cushing’s disease can be maintained over an
extended 24-month time period. However, as changes in the
dose of concomitant medications were not recorded during
the 24-month treatment period, further studies are necessary
to determine the effects of these therapies on the observed
improvements in clinical signs and symptoms. Interestingly,
a subanalysis of patients with hypertension at core baseline
showed that 62.5 % (10/16) of those patients who did not
receive antihypertensive drugs during the core study had a
[5 mmHg decrease in diastolic blood pressure after
12 months of pasireotide treatment [17].
Pasireotide showed a similar safety profile to that of
other somatostatin analogues, except for the increased
frequency and degree of hyperglycemia. The safety profile
of pasireotide following 24 months’ treatment was similar
to that reported at 12 months, with no new safety issues
identified during the extension.
The development of hyperglycemia is a well-character-
ized effect of pasireotide treatment [18]. Plasma glucose and
HbA1c levels increased soon after initiation of pasireotide
but did not deteriorate further over 2 years of treatment. The
stabilization of plasma glucose and HbA1c levels over time
may have resulted from a number of factors, including the
administration of antidiabetic medication, correction of
hypercortisolism, and patient discontinuations. However,
these results should be interpreted with caution because of
the smaller number of patients who entered the extension
phase compared with the 12-month core study. Recent
studies in healthy volunteers showed that hyperglycemia
associated with pasireotide treatment results from a decrease
in incretin and insulin secretion, with no change in insulin
sensitivity [18]. Patients on pasireotide treatment should be
closely monitored for changes in glucose homeostasis, and
prompt intervention is warranted if hyperglycemia occurs.
One limitation of this study is that all the efficacy data are
derived from the 58 patients who entered the extension based
on the achievement of controlled UFC levels or significant
clinical benefit during the core study. As such, it could be
considered that these patients were ‘pre-selected’ for a
positive response to pasireotide. Nevertheless, these data are
encouraging and suggest that patients who have a bio-
chemical response to pasireotide respond rapidly (during the
first 2 months of treatment) and can continue to respond over
a sustained period of time. Non-responders could therefore
be identified soon after initiating pasireotide treatment and
treatment decisions made early in the therapeutic course,
taking into account both biochemical and clinical response.
Of note, the baseline characteristics of the patients entering
the extension were similar to those of the overall core patient
population, with no obvious characteristic predictive of a
positive response to pasireotide treatment.
Table 3 Overall shift in HbA1c from baseline to last available value up to 24-month data cut-off in the 162 patients who received at least one
dose of pasireotide
Baseline Last reported HbA1c value
\5.7 % 5.7 to \6.5 % 6.5 to \8 % C8 % Missing
n (%) n (%) n (%) n (%) n (%) n (%)
\5.7 % 80 (49.4) 14 (8.6) 32 (19.8) 27 (16.7) 2 (1.2) 5 (3.1)
5.7 to \6.5 % 48 (29.6) 2 (1.2) 7 (4.3) 26 (16.0) 12 (7.4) 1 (0.6)
6.5 to \8 % 24 (14.8) 0 0 5 (3.1) 18 (11.1) 1 (0.6)
C8 % 2 (1.2) 0 0 0 2 (1.2) 0
Missing 8 (4.9) 0 3 (1.9) 4 (2.5) 0 1 (0.6)
Total 162 (100.0) 16 (9.9) 42 (25.9) 62 (38.3) 34 (21.0) 8 (4.9)
Italicized values represent the patients with a shift in HbA1c level that indicates a worse diabetic status at the last reported value compared with
core baseline. Two patients with HbA1c C8 % at study entry received pasireotide treatment (one patient in each treatment arm) and were classed
as protocol deviations
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Conclusions
Long-term use of pasireotide resulted in sustained
improvements in mean UFC, serum cortisol and plasma
ACTH. Significant improvements in blood pressure, weight
and total cholesterol were also maintained for the duration
of treatment. The safety profile of pasireotide was typical
for a somatostatin analogue, except for changes in glucose
homeostasis, which need to be closely monitored in patients
receiving pasireotide treatment. This study shows that pa-
sireotide provides sustained clinical benefit, supporting its
use as a treatment for patients with Cushing’s disease.
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